SOTORASIB
20170543
Phase 2 small_molecule active
Quick answer
SOTORASIB for KRAS p.G12C Mutant Advanced Solid Tumors is a Phase 2 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- KRAS p.G12C Mutant Advanced Solid Tumors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active